27.08.2019 • NewsAmgenDede WillamsOtezla

Amgen Makes $13 billion Grab for Otezla

Amgen Makes $13 billion Grab for Otezla
Amgen Makes $13 billion Grab for Otezla

Contrary to recent speculation that Amgen was preparing to buy Alexion, the California-based US biotech has announced that it instead will acquire Celgene’s Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities.

The deal is worth $13.4 billion in cash or around $11.2 billion net of the present value of $2.2 billion in anticipated future cash tax benefits, Amgen said. The transaction’s going ahead is crucial for the acquisition of Celgene by BristolMyers Squibb. Sales of Otezla, driven by strong volume growth, totaled $1.6 billion in in 2018.

Commenting on the purchase, US pharma journal Fierce Pharma said the price “easily dwarfs some recent biopharma deals for entire companies and is significantly above the price tag analysts have previously estimated for Otezla, which suggests an intense bidding process.”

Robert A. Bradway, chairman and CEO of Amgen, said Otezla “fits squarely” with Amgen’s portfolio and is complementary to its existing inflammation franchise of innovative biologics and biosimilar products. He said the company will take advantage of its 20 years of experience in inflammatory disease to realize the franchise’s full global potential as an affordable option for patients with these serious, chronic inflammatory conditions.

The drug already approved in 54 markets outside the US, including the EU and Japan, is claimed to be the leading treatment in the post-topical, pre-biologic segment in its three US indications. It is recommended for patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, as well as in adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease. Otezla has patent exclusivity through at least 2028.

Amgen said the transaction should contribute to its near- and long-term revenue growth rate and will be immediately accretive from close to non-GAAP earnings per share growth, with acceleration thereafter. The company intends to finance the transaction with current balance sheet cash and expects “at least low double-digit sales growth” for Otezla over the next five years.

The number of patients suffering from chronic inflammatory diseases is said to be growing worldwide. Amgen is already a major player in this wide therapeutic category with Enbrel, a blockbuster TNF inhibitor that it markets in the US and Canada. That drug is seen as leading in moderate-to-severe rheumatoid arthritis, moderate-to-severe plaque psoriasis, and psoriatic arthritis (PsA).

Artificial Intelligence

Pierre Racz: "Real Artificial Intelligence Does Not Exist"
part one of a three-part interview series

Pierre Racz: "Real Artificial Intelligence Does Not Exist"

In part one Pierre Racz, President of Genetec, is addressing why IP network video systems were the game changer in the industry and why he does not like the term AI.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

The Start-up Platform for Chemistry & Life Sciences

The tasks range from employee protection, site security and crisis management to IT, OT and production security.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.